References

bekhterev

Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева

V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY

2313-70532713-055X

V. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH

10.31363/2313-7053-2021-57-4-15-35

bekhterev-617

Research Article

НАУЧНЫЕ ОБЗОРЫ

SCIENTIFIC REVIEW

Гены-кандидаты развития антипсихотик-индуцированного паркинсонизма у пациентов с шизофренией

Candidate genes of the development of antipsychotic-induced parkinsonism in patients with schizophrenia

https://orcid.org/0000-0001-6836-9590

Вайман

Е. Э.

Vaiman

E. E.

Елена Эдуардовна Вайман, невролог, младший научный сотрудник центра персонализированной психиатрии и неврологии

192019, г. Санкт-Петербург, ул. Бехтерева, 3

Elena E. Vaiman

St. Petersburg

vaimanelenadoc@gmail.com

https://orcid.org/0000-0002-2840-837X

Шнайдер

Н. А.

Shnayder

N. A.

Наталья Алексеевна Шнайдер, невролог, д.м.н., проф., ведущий научный сотрудник центра персонализированной психиатрии и неврологии; ведущий научный сотрудник Центра коллективного пользования «Молекулярные и клеточные технологии»

192019, г. Санкт-Петербург, ул. Бехтерева, 3; 660022, г. Красноярск, ул. Партизана Железняка, 1

Natalia A. Shnayder

St. Petersburg; Krasnoyarsk

nataliashnayder@gmail.com

https://orcid.org/0000-0001-5618-4206

Незнанов

Н. Г.

Neznanov

N. G.

Николай Григорьевич Незнанов, д.м.н., проф., директор, научный руководитель отделения гериатрической психиатрии

192019, г. Санкт-Петербург, ул. Бехтерева, 3

Nikolay G. Neznanov

St. Petersburg

spbinstb@bekhterev.ru

https://orcid.org/0000-0003-1874-9434

Насырова

Р. Ф.

Nasyrova

R. F.

Регина Фаритовна Насырова, психиатр, клинический фармаколог, д.м.н., главный научный сотрудник, руководитель центра персонализированной психиатрии и неврологии

192019, г. Санкт-Петербург, ул. Бехтерева, 3

Regina F. Nasyrova

St. Petersburg

nreginaf77@gmail.com

Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. БехтереваРоссияV.M. Bekhterev National Medical Research Centre for Psychiatry and NeurologyRussian Federation

Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева; Красноярский государственный медицинский университет им. Проф. В.Ф. Войно-ЯсенецкогоРоссияV.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; V. F. Voyno-Yasenetsky Krasnoyarsk State Medical UniversityRussian Federation

2021

29122021

5541535

2021

Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф.

Vaiman E.E., Shnayder N.A., Neznanov N.G., Nasyrova R.F.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.bekhterevreview.com/jour/article/view/617

Антипсихотик-индуцированный паркинсонизм—нежелательная реакция со стороны экстрапирамидной системы, возникающая на фоне приема антипсихотиков (АП), чаще у пациентов с шизофренией. АП-индуцированный паркинсонизм (АИП) относится к группе вторичного паркинсонизма. Его распространенность в мире составляет около 36%. Предполагается, что эта нежелательная реакция (НР) генетически детерминирована. В последние годы проведены многочисленные ассоциативные генетические исследования предрасположенности к развитию АИП. Однако, результаты исследований противоречивы.Цель. Обзор результатов исследований генетических предикторов развития антипсихотик-индуцированного паркинсонизма у пациентов с шизофренией.Материалы и методы. Нами проведен поиск полнотекстовых публикаций на русском и английском языках в базах данных РИНЦ, PubMed, Web of Science, Springer, используя ключевые слова и комбинированные поиски слов за последнее 10-летие.Результаты. В обзоре рассмотрены гены-кандидаты, кодирующие белки/ферменты, участвующие в фармакодинамике и фармакокинетике АП. Нами проанализировано 23 ассоциативных генетических исследования, изучающих 108 генетических вариаций, включая ОНВ/полиморфизмы 26 геновкандидатов, участвующих в развитии АИП у пациентов с шизофренией. Среди такого множества полученных результатов выявлено всего 22 положительные ассоциации: rs1799732 (141CIns / Del), rs1800497 (C/T), rs6275 (C/T) DRD2; rs167771 (G/A) DRD3; VNTR*9R DAT1; rs4680 (G/A) СOMT; rs6311 (C/T) 5HTR2A; rs6318 (C/G), rs3813929 (С/Т), гаплотип -997G, -759C, -697C и 68G HTR2C; rs2179652 (C/T), rs2746073 (T/A), rs4606 (C/G), rs1152746 (A/G), rs1819741 (С/Т), rs1933695 (G/A), гаплотип rs1933695-G, rs2179652-C, rs4606-C, rs1819741-T и rs1152746-G, гаплотип rs1933695-G, rs2179652-T, rs4606-G, rs1819741-C и rs1152746-A RGS2; Гаплотип TCCTC ADORA2A; rs4795390 (C/G) PPP1R1B; rs6265 (G/A) BDNF; rs12678719 (C/G) ZFPM2; rs938112 (C/A) LSMAP; rs2987902 (A/T) ABL1; HLA-B44; rs16947 (A/G), rs1135824 (A/G), rs3892097 (A/G), rs28371733 (A/G), rs5030867 (A/C), rs5030865 (A/C), rs1065852 (C/T), rs5030863 (C/G), rs5030862 (A/G), rs28371706 (C/T), rs28371725 (A/G), rs1080983 (A/G) CYP2D6. Однако, в настоящее время следует признать, что нет окончательного или единственного решения о ведущей роли какого-либо конкретного ОНВ/полиморфизма в развитии АИП.Заключение. Раскрытие генетических предикторов развития АИП, как наиболее распространенной неврологической НР при лечении пациентов с психиатрическими расстройствами, может дать ключ к разработке стратегии персонализированной профилактики и терапии рассматриваемого осложнения АП-терапии шизофрении в реальной клинической практике.

Antipsychotic-induced parkinsonism is an undesirable reaction from the extrapyramidal system that occurs against the background of taking antipsychotics (AP), more often in patients with schizophrenia. Antipsychotic-induced parkinsonism belongs to the group of secondary parkinsonism. Its prevalence in the world is about 36%. It is assumed that this undesirable AP reaction is genetically determined. In recent years, numerous associative genetic studies of predisposition to the development of antipsychotic-induced parkinsonism have been conducted. However, the research results are contradictory.Purpose. Review of the results of studies of genetic predictors of antipsychotic-induced parkinsonism in patients with schizophrenia.Materials and methods. We searched for full-text publications in Russian and English in the RSCI, PubMed, Web of Science, Springer databases using keywords and combined searches for words over the past decade.Results. The review considers candidate genes encoding proteins/enzymes involved in the pharmacodynamics and pharmacokinetics of AP. We analyzed 23 genome-wide studies examining 108 genetic variations, including SNV/polymorphisms of 26 candidate genes involved in the development of AIP in schizophrenic patients. Among such a set of obtained results, only 22 positive associations were revealed: rs1799732 (141CIns/Del), rs1800497 (C/T), rs6275 (C/T) DRD2; rs167771 (G/A) DRD3; VNTR*9R DAT1; rs4680 (G/A) СOMT; rs6311 (C/T) 5HTR2A; rs6318 (C/G), rs3813929 (С/Т), haplotype-997G, -759C, -697C и 68G HTR2C; rs2179652 (C/T), rs2746073 (T/A), rs4606 (C/G), rs1152746 (A/G), rs1819741 (С/Т), rs1933695 (G/A), haplotype rs1933695-G, rs2179652-C, rs4606-C, rs1819741-T и rs1152746-G, haplotype rs1933695-G, rs2179652-T, rs4606-G, rs1819741-C и rs1152746-A RGS2; haplotype TCCTC ADORA2A; rs4795390 (C/G) PPP1R1B; rs6265 (G/A) BDNF; rs12678719 (C/G) ZFPM2; rs938112 (C/A) LSMAP; rs2987902 (A/T) ABL1; HLA-B44; rs16947 (A/G), rs1135824 (A/G), rs3892097 (A/G), rs28371733 (A/G), rs5030867 (A/C), rs5030865 (A/C), rs1065852 (C/T), rs5030863 (C/G), rs5030862 (A/G), rs28371706 (C/T), rs28371725 (A/G), rs1080983 (A/G) CYP2D6. However, at the present time it should be recognized that there is no final or unique decision about the leading role of any particular SNV/polymorphism in the development of AIP.Conclusion. Disclosure of genetic predictors of AP-induced parkinsonism development may provide a key to the development of a strategy for personalized prevention and treatment of the neurological complication of AP-therapy of schizophrenia in real clinical practice.

антипсихотик-индуцированный паркинсонизмлекарственно-индуцированный паркинсонизмантипсихотикигеныDRD2DRD3DAT1СOMT5HTR2AHTR2CRGS2RGS4RGS8RGS9ANNK1PPP1R1BATP1A3ADORA1ADORA2AADORA3BDNFMnSOD (SOD2)ZFPM2LSMAPABL1NQO1GSTP1HLA-BCYP1A2CYP2D6

antipsychotics-induced parkinsonismdrug-induced parkinsonismantipsychoticsgenesDRD2DRD3DAT1СOMT5HTR2AHTR2CRGS2RGS4RGS8RGS9ANNK1PPP1R1BATP1A3ADORA1ADORA2AADORA3BDNFMnSOD (SOD2)ZFPM2LSMAPABL1NQO1GSTP1HLA-BCYP1A2CYP2D6

References1

Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф. Лекарственно-индуцированный паркинсонизм. Социальная и клиническая психиатрия. 2021; 31(1):96-103.

Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Druginduced parkinsonism. Sotsial’naya i klinicheskaya psikhiatriya. 2021; 31(1):96-103. (In Russ.)

Вайман Е.Э., Шнайдер Н.А., Незнанов Н.Г., Насырова Р.Ф. Методы диагностики лекарственноиндуцированного паркинсонизма: обзор отечественной и зарубежной литературы. Сибирский вестник психиатрии и наркологии. 2020; 4(109):64-72. https://doi.org/10.26617/1810-3111-2020-4(109)-64-72

Vaiman EE, Schneider NA, Neznanov NG, Nasyrova RF. Diagnostic methods for drug-induced parkinsonism: a review of Russian and foreign literature. Sibirskii vestnik psikhiatrii i narkologii. 2020; 4(109):64-72. (In Russ.) https://doi.org/10.26617/1810-3111-2020-4(109)-64-72

Сосин Д.Н., Иванов М.В., Муслимова Л.М., Иващенко Д.В., Сычев Д.А. Отсутствие ассоциации полиморфных вариантов rs1065852 и rs3892097 гена CYP2D6 с терапевтической резистентностью при шизофрении. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2019; 4:128-129. https://doi.org/10.31363/2313-7053-2019-4-1-128-129

Sosin DN, Ivanov MV, Muslimova LM, Ivashchenko DV, Sychev DA. No association of rs1065852 and rs3892097 polymorphisms gene CYP2D6 with treatment resistant schizophrenia. Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. 2019;(4-1):128-129. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-1-128-129

Хубларова Л.А., Захаров Д.В., Михайлов В.А. Стратификация риска развития поздних лекарственно-индуцированных осложнений. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2017; 4:111-114.

Khublarova LA, Zakharov DV, Mikhaylov VA. Stratification of the risk of developing tardive drug-induced complications. Obozrenie psikhiatrii i meditsinskoi psikhologii imeni V.M. Bekhtereva. 2017; 4:111-114. (In Russ.)

Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics. 2005; 5(3):149-60.

Al Hadithy AF, Wilffert B, Bruggeman R, Stewart RE, Brouwers JR, Matroos GE, et al. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol. 2009; 24(2):123-8. https://doi.org/10.1002/hup.997

Al Hadithy AF, Wilffert B, Stewart RE, Looman NM, Bruggeman R, Brouwers JR, et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet. 2008; 147B(6):890-897. https://doi.org/10.1002/ajmg.b.30746

Arranz MJ, Gallego C, Salazar J, Arias B. Pharmacogenetic studies of drug response in schizophrenia. Expert Review of Precision Medicine and Drug Development. 2016: 1(1):79-91. https://doi.org/10.1080/23808993.2016.1140554

Asselmann E, Hertel J, Schmidt CO, Homuth G, Nauck M, Beesdo-Baum K, et al. Interplay between RGS2 and childhood adversities in predicting anxiety and depressive disorders: Findings from a general population sample. Depress Anxiety. 2018; 35(11):1104-1113. https://doi.org/10.1002/da.22812

Bakker PR, Bakker E, Amin N, van Duijn CM, van Os J, van Harten PN. Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study. PLoS One. 2012; 7(5):e36561. https://doi.org/10.1371/journal.pone.0036561

Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000; 5(4):410-417. https://doi.org/10.1038/sj.mp.4000736

Benians A, Nobles M, Hosny S, Tinker A. Regulators of G-protein signaling form a quaternary complex with the agonist, receptor, and G-protein. A novel explanation for the acceleration of signaling activation kinetics. J Biol Chem. 2005; 280(14):13383-13394. https://doi.org/10.1074/jbc.M410163200

Boloc D, Rodríguez N, Torres T, García-Cerro S, Parellada M, Saiz-Ruiz J, et al. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. Psychopharmacology (Berl). 2020; 237(7):2151- 2159. https://doi.org/10.1007/s00213-020-05526-8

Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 2005; 27(4):539-543. https://doi.org/10.1097/01.ftd.0000164609.14808.93

Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999; 60(7):469-476. PMID:10453802

Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002; 72(4):438-452. https://doi.org/10.1067/mcp.2002.127494

Bruzzese A, Dalton JAR, Giraldo J. Insights into adenosine A2A receptor activation through cooperative modulation of agonist and allosteric lipid interactions. PLoS Comput Biol. 2020; 16(4):e1007818. https://doi.org/10.1371/journal.pcbi.1007818

Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004; 75(5):807-821. https://doi.org/10.1086/425589

Ciancetta A, Rubio P, Lieberman DI, Jacobson KA. A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states. J Comput Aided Mol Des. 2019; 33(11):983-996. https://doi.org/10.1007/s10822-019-00246-4

Crisafulli C, Drago A., Sidoti A, Serretti A. A Genetic Dissection of Antipsychotic Induced Movement Disorders. Current Medicinal Chemistry. 2013; 20:312-330. PMID:23157623

de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005; 66(1):15-27. https://doi.org/10.4088/jcp.v66n0103

Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014; 656370. https://doi.org/10.1155/2014/656370

Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004; 24(2):214-219. https://doi.org/10.1097/01.jcp.0000116646.91923.2f.

Ferrari M, Bolla E, Bortolaso P, Callegari C, Poloni N, Lecchini S, et al. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res. 2012; 200(2-3):1014-1017. https://doi.org/10.1016/j.psychres.2012.07.002

Friedman JH. Viewpoint: challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism RelatDisord. 2014; 20(12):1325-1328. https://doi.org/10.1016/j.parkreldis.2014.09.030

Gassó P, Mas S, Bernardo M, Alvarez S, Parellada E, Lafuente A. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009; 9(6):404-410. https://doi.org/10.1038/tpj.2009.26

Gassó P, Mas S, Oliveira C, Bioque M, Parellada E, Bernardo M, et al. Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. Eur Neuropsychopharmacol. 2011;2 1(4):294-299. https://doi.org/10.1016/j.euroneuro.2010.06.006

Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A. 1998; 95(17):9991-9996. https://doi.org/10.1073/pnas.95.17.9991

Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T, et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. Psychopharmacology (Berl). 2012; 220(3):519-528. https://doi.org/10.1007/s00213-011-2499-6

Greenbaum L, Smith RC, Rigbi A, Strous R, Teltsh O, Kanyas K, et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3’-untranslated region. Pharmacogenomics J. 2009; 9(2):103-110. https://doi.org/10.1038/tpj.2008.6

Greenbaum L, Strous RD, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics. 2007; 17(7):519-528. https://doi.org/10.1097/FPC.0b013e32800ffbb4

Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol. 2008; 64(5):477-482. https://doi.org/10.1007/s00228-007-0450-x

Gunes A, Scordo MG, Jaanson P, Dahl ML. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl). 2007; 190(4):479-484. https://doi.org/10.1007/s00213-006-0622-x

Güzey C, Scordo MG, Spina E, Landsem VM, Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol. 2007; 63(3):233-241. https://doi.org/10.1007/s00228-006-0234-8

Haq IU, Snively BM, Sweadner KJ, Suerken CK, Cook JF, Ozelius LJ, et al. Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing. Mov Disord. 2019; 34(10):1528-1536. https://doi.org/10.1002/mds.27801

Higa M, Ohnuma T, Maeshima H, Hatano T, Hanzawa R, Shibata N, et al. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett. 2010; 469(1):55-59. https://doi.org/10.1016/j.neulet.2009.11.043

Hill AL, Sun B, McDonnel DP. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment Hill with long-acting injection (Depot) or oral formulations of olanzapine. Clin Schizophrenia Relat Psychoses. 2014; 7:216-222.

Holmans P. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet. 2010; 72:141-179.

Jönsson EG, Saetre P, Nyholm H, Djurovic S, Melle I, Andreassen OA, et al. Lack of association between the regulator of G-protein signaling 4 (RGS4) rs951436 polymorphism and schizophrenia. Psychiatr Genet. 2012; 22(5):263-264. https://doi.org/10.1097/YPG.0b013e32834f3558

Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol. 2009; 29(3):272-277. https://doi.org/10.1097/JCP.0b013e3181a289e0

Kasten M, Brüggemann N, König IR, Doerry K, Steinlechner S, Wenzel L, et al. Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl). 2011; 214(3):729-736. https://doi.org/10.1007/s00213-010-2079-1

Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004; 9(5):442-473. https://doi.org/10.1038/sj.mp.4001494

Knol W, van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B, et al. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol. 2013; 33(3):405-410. https://doi.org/10.1097/JCP.0b013e3182902708

Kodama D, Tanaka M, Matsuzaki T, Izumo K, Nakano N, Matsuura E, et al. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis. 2020; 14(7):e0008361. https://doi.org/10.1371/journal.pntd.0008361

Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, et al. Genetic Risk and Outcome in Psychosis (GROUP) investigators. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl). 2012; 219(3):727-736. https://doi.org/10.1007/s00213-011-2394-1

Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res. 2007; 90(1-3):115-122. https://doi.org/10.1016/j.schres.2006.09.031

Luo J, Li S, Qin X, Peng Q, Liu Y, Yang S, et al. Association of the NQO1 C609T polymorphism with Alzheimer’s disease in Chinese populations: a metaanalysis. Int J Neurosci. 2016; 126(3):199-204. https://doi.org/10.3109/00207454.2015.1004573

Ma H, Li X, Lin A, Yuan Z, Zhou J, Yang X, et al. Associations Between PPP1R1B Gene Polymorphisms and Anxiety Levels in the Chinese Population. Neurosci Bull. 2017; 33(1):107-110. https://doi.org/10.1007/s12264-016-0088-8

Mas S, Gassó P, Lafuente A. Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example. Pharmacogenomics. 2015; 16(17):1975-1988. https://doi.org/10.2217/pgs.15.134

Mas S, Gassó P, Ritter MA, Malagelada C, Bernardo M, Lafuente A. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol. 2015; 25(1):51-59. https://doi.org/10.1016/j.euroneuro.2014.11.011

Metzer WS, Newton JE, Steele RW, Claybrook M, Paige SR, McMillan DE, et al. HLA antigens in drug-induced parkinsonism. Mov Disord. 1989; 4(2):121-128. https://doi.org/10.1002/mds.870040203

Muscettola G., Barbato G., Pampallona S., Cassielo M., Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol. 1999; 19:203e8.

Naumovska Z, Nestorovska AK, Filipce A, Sterjev Z, Brezovska K, Dimovski A, et al. Pharmacogenetics and antipsychotic treatment response. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015; 36(1):53-67. PMID:26076775

Nasrollahi-Shirazi S, Szöllösi D, Yang Q, Muratspahic E, El-Kasaby A, Sucic S, et al. Functional Impact of the G279S Substitution in the Adenosine A1-Receptor (A1RG279S7.44), a Mutation Associated with Parkinson’s Disease. Mol Pharmacol. 2020; 98(3):250-266. https://doi.org/10.1124/molpharm.120.000003

Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004; 23(6):540-545. https://doi.org/10.1002/humu.20039

Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G. BDNF as a Promising Therapeutic Agent in Parkinson’s Disease. Int J Mol Sci. 2020; 21(3):1170. https://doi.org/10.3390/ijms21031170

Plesnicar BK, Zalar B, Breskvar K, Dolzan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol. 2006; 20(6):829-833. https://doi.org/10.1177/0269881106062894

Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res. 2013; 149(1-3):1-14. https://doi.org/10.1016/j.schres.2013.06.035

Salminen LE, Schofield PR, Pierce KD, Bruce SE, Griffin MG, Tate DF, et al. Vulnerability of white matter tracts and cognition to the SOD2 polymorphism: A preliminary study of antioxidant defense genes in brain aging. Behav Brain Res. 2017; 329:111-119. https://doi.org/10.1016/j.bbr.2017.04.041

Sanchez-Gistau V, Mariné R, Martorell L, Cabezas A, Algora MJ, Sole M, et al. Relationship between ANKK1 rs1800497 polymorphism, overweight and executive dysfunction in early psychosis. Schizophr Res. 2019; 209:278-280. https://doi.org/10.1016/j.schres.2019.05.022

Snpedia. [https://www.snpedia.com]. Snpedia; 2020 [Обновлено 23 июля 2015, процитировано 25 ноября 2020]. Доступно: https://www.snpedia.com/index.php/CYP3A5

Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990; 347(6289):146-151. https://doi.org/10.1038/347146a0

Sparkes RS, Lan N, Klisak I, Mohandas T, Diep A, Kojis T, et al. Assignment of a serotonin 5HT2 receptor gene (HTR2) to human chromosome 13q14-q21 and mouse chromosome 14. Genomics. 1991; 9(3):461-465. https://doi.org/10.1016/0888-7543(91)90411-7

Tagai N, Tanaka A, Sato A, Uchiumi F, Tanuma SI. Low Levels of Brain-Derived Neurotrophic Factor Trigger Self-aggregated Amyloid β-Induced Neuronal Cell Death in an Alzheimer’s Cell Model. Biol Pharm Bull. 2020; 43(7):1073-1080. https://doi.org/10.1248/bpb.b20-00082

Turčin A, Dolžan V, Porcelli S, Serretti A, Plesničar BK. Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Non-acute Schizophrenia. OMICS. 2016; 20(5):283-289. https://doi.org/10.1089/omi.2016.0003

Usiello A, Baik JH, Rougé-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408(6809):199-203. https://doi.org/10.1038/35041572

Vandenbergh DJ, Persico AM, Uhl GR. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res Mol Brain Res. 1992; 15(1-2):161-166. https://doi.org/10.1016/0169-328x(92)90165-8

Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical non-recognition of neuroleptic induced movement disorders: a cautionary study. Am J Psychiatry. 1987; 144:1148e53

Yang Y, Yin F, Hang Q, Dong X, Chen J, Li L, et al. Regulation of Endothelial Permeability by Glutathione S-Transferase Pi Against Actin Polymerization. Cell Physiol Biochem. 2018; 45(1):406-418. https://doi.org/10.1159/000486918

Zhu YS, Li YX, Qiao XM, Zhang HB. Regulators of G-protein signaling 9 genetic variations in Chinese subjects with schizophrenia. Genet Mol Res. 2015; 14(3):8458-8465. https://doi.org/10.4238/2015.July.28.13

The authors declare that there are no conflicts of interest present.